Celularity (CELU) Competitors $2.09 -0.03 (-1.42%) As of 01:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. IPHA, VTYX, DERM, PBYI, DMAC, SPRO, ALMS, DRUG, VYGR, and ELDNShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), Spero Therapeutics (SPRO), Alumis (ALMS), Bright Minds Biosciences (DRUG), Voyager Therapeutics (VYGR), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Innate Pharma Ventyx Biosciences Journey Medical Puma Biotechnology DiaMedica Therapeutics Spero Therapeutics Alumis Bright Minds Biosciences Voyager Therapeutics Eledon Pharmaceuticals Celularity (NASDAQ:CELU) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk. Which has more volatility & risk, CELU or IPHA? Celularity has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Does the media prefer CELU or IPHA? In the previous week, Celularity had 2 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Celularity and 0 mentions for Innate Pharma. Celularity's average media sentiment score of 0.36 beat Innate Pharma's score of 0.00 indicating that Celularity is being referred to more favorably in the media. Company Overall Sentiment Celularity Neutral Innate Pharma Neutral Do institutionals & insiders believe in CELU or IPHA? 19.0% of Celularity shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 22.1% of Celularity shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend CELU or IPHA? Innate Pharma has a consensus price target of $11.00, suggesting a potential upside of 521.82%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger earnings and valuation, CELU or IPHA? Innate Pharma has lower revenue, but higher earnings than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$54.22M0.92-$57.89M-$2.65-0.79Innate Pharma$12.62M12.92-$53.53MN/AN/A Is CELU or IPHA more profitable? Innate Pharma has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Innate Pharma's return on equity of 0.00% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-106.77% -271.88% -42.82% Innate Pharma N/A N/A N/A SummaryInnate Pharma beats Celularity on 10 of the 15 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.06M$2.96B$5.58B$9.01BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-0.7921.4727.5120.20Price / Sales0.92259.84415.84172.51Price / CashN/A41.8337.0657.97Price / Book5.657.788.085.61Net Income-$57.89M-$55.05M$3.17B$248.50M7 Day Performance1.95%5.38%3.57%4.92%1 Month Performance6.36%3.87%3.74%7.42%1 Year Performance-25.89%5.72%33.78%21.48% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.1874 of 5 stars$2.09-1.4%N/A-30.9%$50.06M$54.22M-0.79220Upcoming EarningsIPHAInnate Pharma3.134 of 5 stars$1.82-1.9%$11.00+506.1%-16.1%$170.53M$21.77M0.00220VTYXVentyx Biosciences2.4005 of 5 stars$2.14-8.5%$10.00+367.3%+2.6%$166.52MN/A-1.2230DERMJourney Medical1.8496 of 5 stars$7.18+0.6%$9.50+32.3%+27.3%$166.33M$56.13M-18.4190PBYIPuma Biotechnology3.9175 of 5 stars$3.43+3.0%$7.00+104.1%+18.4%$165.27M$230.50M4.45200DMACDiaMedica Therapeutics1.1241 of 5 stars$3.90+1.6%$8.00+105.1%+27.1%$164.67MN/A-6.0920SPROSpero Therapeutics3.8918 of 5 stars$2.90-1.4%$5.00+72.4%+124.4%$164.38M$47.98M-2.27150ALMSAlumis3.0787 of 5 stars$3.00-0.7%$22.86+661.9%N/A$164.30MN/A0.00N/ADRUGBright Minds Biosciences2.7101 of 5 stars$26.11+12.2%$83.25+218.8%+2,493.2%$163.91MN/A-72.53N/APositive NewsGap UpVYGRVoyager Therapeutics3.8261 of 5 stars$3.11+5.1%$13.39+330.5%-56.5%$163.80M$80M-2.13100High Trading VolumeELDNEledon Pharmaceuticals2.0094 of 5 stars$2.71+0.7%$9.00+232.1%+36.5%$161.08MN/A-1.2910News Coverage Related Companies and Tools Related Companies IPHA Competitors VTYX Competitors DERM Competitors PBYI Competitors DMAC Competitors SPRO Competitors ALMS Competitors DRUG Competitors VYGR Competitors ELDN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
